Paper · 41420106
Mechanisms of resistance to VHL loss-induced genetic and pharmacological vulnerabilities.
Ge J and 12 others. EMBO Mol Med, 2026. Cited by 2 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Mechanisms of resistance to VHL loss-induced genetic and pharmacological vulnerabilities. Papers, record 41420106. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41420106
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Mechanisms of resistance to VHL loss-induced genetic and pharmacological vulnerabilities.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Von Hippel-Lindau Tumor Suppressor Protein | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Antineoplastic Agents | Major topic |
| Humans | |
| Hypoxia-Inducible Factor 1, alpha Subunit | |
| CRISPR-Cas Systems | |
| Cell Line, Tumor | |
| Epithelial Cells |
Source PubMed
Grants7
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| C9685/A25177 | Cancer Research UK (CRUK) | PubMed | ||
| C62187/A29760 | Cancer Research UK (CRUK) | PubMed | ||
| BRC-1215-20014 | NIHR | NIHR Cambridge Biomedical Research Centre (NIHR Cambridge BRC) | PubMed | ||
| 955951 | European Commission (EC) | PubMed | ||
| MC_UU_12022/7 | UKRI | Medical Research Council (MRC) | PubMed | ||
| RP_033_20170303 | Kidney Research UK | PubMed | ||
| 338420 | Research Council of Finland (AKA) | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39,468,210 | The present and future of the Cancer Dependency Map. | Nat Rev Cancer | 2025 | https://conductscience.org/library/papers/39468210 | PubMed |
| 2 | 35,042,991 | PROTAC targeted protein degraders: the past is prologue. | Nat Rev Drug Discov | 2022 | https://conductscience.org/library/papers/35042991 | PubMed |
| 3 | 39,320,914 | Total loss of VHL gene function impairs neuroendocrine cancer cell fitness due to excessive HIF2α activity. | Proc Natl Acad Sci U S A | 2024 | https://conductscience.org/library/papers/39320914 | PubMed |
| 4 | 22,455,463 | clusterProfiler: an R package for comparing biological themes among gene clusters. | OMICS | 2012 | https://conductscience.org/library/papers/22455463 | PubMed |
| 5 | 36,329,119 | Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders. | Nat Chem Biol | 2023 | https://conductscience.org/library/papers/36329119 | PubMed |
| 6 | 32,807,776 | HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice. | Nat Commun | 2020 | https://conductscience.org/library/papers/32807776 | PubMed |
| 7 | 21,428,443 | Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. | ACS Chem Biol | 2011 | https://conductscience.org/library/papers/21428443 | PubMed |
| 8 | 29,656,894 | Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. | Cell | 2018 | https://conductscience.org/library/papers/29656894 | PubMed |
| 9 | 41,820,368 | VHL synthetic lethality screens uncover CBF-β as a negative regulator of STING. | Nat Commun | 2026 | https://conductscience.org/library/papers/41820368 | PubMed |
| 10 | 16,517,406 | HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. | Cell Metab | 2006 | https://conductscience.org/library/papers/16517406 | PubMed |
1 to 10 of 33
See all 33 referencesCited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,593,521 | Recent advances in etiology and treatment of von Hippel-Lindau Disease (VHLD). | Cancer Metastasis Rev | 2026 | https://conductscience.org/library/papers/42593521 | PubMed |
| 42,313,274 | Von Hippel-Lindau disease: pathophysiological and clinical advances. | Fam Cancer | 2026 | https://conductscience.org/library/papers/42313274 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ARNT | 405 | PubTator's text mining | https://conductscience.org/library/genes/405 | NCBI Gene |
| HIF1A | 3,091 | PubTator's text mining | https://conductscience.org/library/genes/3091 | NCBI Gene |
| VHL | 7,428 | PubTator's text mining | https://conductscience.org/library/genes/7428 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41420106
GET https://conductscience.org/api/papers/v1/41420106/references?page=2